The ROE as of December 2024 (TTM) for DICE Therapeutics, Inc. (DICE) is 56.07%

According to DICE Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 56.07%. This represents a change of 3.12% compared to the average of 1.74% of the last 4 quarters.

DICE Therapeutics, Inc. (DICE) Historical ROE (quarterly & annually)

How has DICE ROE performed in the past?

The mean historical ROE of DICE Therapeutics, Inc. over the last ten years is 44.68%. The current 56.07% ROE has changed 25.48% with respect to the historical average. Over the past ten years (40 quarters), DICE's ROE was at its highest in in the December 2021 quarter at 15.62%. The ROE was at its lowest in in the June 2022 quarter at -7.82%.

DICE Therapeutics, Inc. (DICE) ROE by Quarter and Year

Discovering the peaks and valleys of DICE Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

DICE Therapeutics, Inc. (DICE) Average ROE

How has DICE ROE performed in the past?

The current ROE of DICE Therapeutics, Inc. (DICE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

DICE Therapeutics, Inc. (DICE) ROE vs. Peers

How is DICE’s ROE compared to its peers?

DICE Therapeutics, Inc.’s ROE is greater than Nuvalent, Inc. (-28.63%), greater than Arcellx, Inc. (-8.28%), greater than Vaxcyte, Inc. (-23.53%), greater than Viridian Therapeutics, Inc. (-45.47%), greater than Ventyx Biosciences, Inc. (-54.94%), greater than Immunocore Holdings plc (-14.67%), less than Cytokinetics, Incorporated (335.19%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Karuna Therapeutics, Inc. (-25.23%), greater than Dyne Therapeutics, Inc. (-57.46%), greater than Chinook Therapeutics, Inc. (-41.23%), greater than Pliant Therapeutics, Inc. (-48.91%), greater than Crinetics Pharmaceuticals, Inc. (-36.12%), less than Ascendis Pharma A/S (212.63%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Acumen Pharmaceuticals, Inc. (-32.99%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), greater than MoonLake Immunotherapeutics (-15.78%),

Build a custom stock screener for DICE Therapeutics, Inc. (DICE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like DICE Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

DICE Therapeutics, Inc. (DICE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like DICE Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.